Share
News
-
28 June 2011 /Prices and reimbursement
Decision on future reimbursement status of medicines in ATC group C05 (vasoprotectives)
On 27 June 2011, the Danish Medicines Agency decided on the future reimbursement status of medicines in ATC group C05 (vasoprotectives). These medicines will still not be eligible for general reimbursement.
-
14 June 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Efient®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Efient®. The product has been granted general reimbursement.
-
27 May 2011 /Prices and reimbursement
Consultation on the Reimbursement Committee's recommendation for glucosamine
The Reimbursement Committee has reassessed the reimbursement status of glucosamine-containing medicines. Glucosamine-containing medicines are used for the alleviation of painful osteoarthritis. The Reimbursement Committee recommends removing general conditional reimbursement for these medicines.
-
27 May 2011 /Prices and reimbursement
Online application for general reimbursement for medicines
Pharmaceutical companies now have the possibility to apply online for general reimbursement via DKMAnet.
-
24 May 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Xeplion®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Xeplion®. The product is eligible for general reimbursement from 30 May 2011.
-
06 May 2011 /Prices and reimbursement
Consultation on the Reimbursement Committee’s recommendation concerning the reimbursement status of medicines for treatment of depression and anxiety (medicines in ACT group N06A, etc.)
At the Danish Medicines Agency’s request, the Reimbursement Committee has reassessed the reimbursement status of medicines in ATC group N06A, antidepressants, as well as certain medicines in ATC groups N03A, N05A and N05B.
-
05 May 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Trobalt®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Trobalt®. The product is eligible for general reimbursement from 16 May 2011.
-
20 April 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Grazax®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Grazax®. The product is eligible for general conditional reimbursement from 2 May 2011.
-
14 April 2011 /Prices and reimbursement
Use the conditional reimbursement scheme correctly – the opposite is misuse of society’s money and puts patient safety at risk
The Danish Medical Association and the Danish Medicines Agency urge doctors to use the conditional reimbursement scheme correctly - the opposite is misuse of society’s money and puts patient safety at risk
-
14 March 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Brilique®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Brilique®. The product has been granted general reimbursement.
-
03 March 2011 /Prices and reimbursement
The Danish Medicines Agency begins ad hoc reassessment of reimbursement status of glucosamine (M01AX05)
Clinical studies have called into question the efficacy of glucosamine for the alleviation of painful osteoarthritis. This has contributed to the Danish Medicines Agency’s decision to initiate ad hoc reassessment of glucosamine-containing medicines, which today have general conditional reimbursement when prescribed for the alleviation of symptoms of mild to moderate osteoarthritis and when prescribed to old-age pensioners.
-
22 February 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Sycrest®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Sycrest®. The product has been granted general reimbursement.
-
22 February 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Targin®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Targin®. The product is neither eligible for general nor general conditional reimbursement.
-
15 February 2011 /Prices and reimbursement
Applications for general reimbursement in 2010
In 2010, the Danish Medicines Agency reviewed 21 cases on general reimbursement for medicines. Nine medicines were granted general reimbursement or general conditional reimbursement, and the remaining 12 medicines were refused general reimbursement, one of which maintained general conditional reimbursement.
-
02 February 2011 /Prices and reimbursement
Review concluded regarding general reimbursement for Palexia Depot®
The Danish Medicines Agency has completed its review of an application for general reimbursement for Palexia Depot®. The product has been granted general reimbursement.
-
11 January 2011 /Prices and reimbursement
Reassessment of reimbursement status of medicines for treatment of depression and anxiety disorders
On 22 December 2009, the Danish Medicines Agency announced that it would begin reassessing the reimbursement status of medicines in ATC group N
